ProPhase Labs Operating Expenses 2010-2025 | PRPH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ProPhase Labs operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ProPhase Labs operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$69.3B
Zoetis (ZTS)	$67.6B
Takeda Pharmaceutical (TAK)	$47B
Daiichi Sankyo, - (DSNKY)	$46.1B
BeOne Medicines - (ONC)	$33.7B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$20B
Merck (MKKGY)	$16.8B
Shionogi (SGIOY)	$15.5B
United Therapeutics (UTHR)	$14B
Neurocrine Biosciences (NBIX)	$13.1B
Orion OYJ (ORINY)	$10.8B
IPSEN (IPSEY)	$10.6B
Madrigal Pharmaceuticals (MDGL)	$8.3B
Corcept Therapeutics (CORT)	$7.7B
Grifols, S.A (GRFS)	$7.3B
Ionis Pharmaceuticals (IONS)	$6.9B
Stevanato Group S.p.A (STVN)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.3B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4.3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.8B
Hypermarcas (HYPMY)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.2B
Endo (NDOI)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B